



## **CME INFORMATION**

### **CVI Webinar Series: Synergy of Drugs and Device for Treating PAD: A Concerted Approach to Improve Patient Outcomes**

**April 14, 2021 – April 14, 2022**

#### **TARGET AUDIENCE**

This activity has been designed to meet the educational needs of cardiologists, surgeons, internists, trainees, investigators, and allied health care workers who participate in the care of patients with coronary, peripheral, and structural cardiovascular diseases.

#### **EDUCATIONAL GOAL**

The goal of this activity is to provide participants with knowledge and state-of-the-art management information on how to evaluate and treat patients with coronary artery disease, peripheral vascular disease, and valvular, structural heart and arrhythmic heart disease.

#### **LEARNING OBJECTIVES**

- Identify benefits of DCB and DES over BMS and PTA
- Explain advantages and disadvantages of DCB over DES
- Describe the concept of leave nothing behind
- Explain global data on drug delivery for long lesions

#### **ACCREDITATION**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of *CMEsolutions* and Cardiovascular Innovations Foundation. The *CMEsolutions* is accredited by the ACCME to provide continuing medical education for physicians.

The *CMEsolutions* designates this enduring internet activity for a maximum of 1 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Start Date:** April 14, 2021

**End Date:** April 14, 2022

#### **FEES**

There is no registration fee for this activity.

#### **PARTICIPATION REQUIREMENTS**

1. View webinar
2. Beginning 4/17/2021, login to:  
<https://online-med-edu.com/cvi2020/webinar/synergy>
3. Complete the Evaluation/Credit Request Form

## 4. Download or Print Credit Statement

### **FACULTY AND DISCLOSURES**

*CMEsolutions* requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by *CMEsolutions* for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. *CMEsolutions* has mitigated all conflicts of interest prior to this educational activity.

#### ***Subhash Banerjee, MD***

Chief of Cardiology, VA North Texas Health Care System

Dallas, TX

Has disclosed the following relevant financial relationships: AstraZeneca-Speaker Bureau; Boston Scientific-Institutional Research Grant; Livmore, Inc.-Consultant

#### ***Mehdi Shishebor, DO, MPH, PhD***

Director, Cardiovascular Interventional Center, University Hospitals Cleveland Medical Center  
Cleveland, OH

Mehdi Shishebor has disclosed the following relevant financial relationships: Abbott Vascular, Boston Scientific Corporation, Medtronic, Philips, and Terumo- Advisory Board

#### ***Manesh R. Patel, MD***

Director, Cardiovascular Interventional Center, University Hospitals Cleveland Medical Center  
Durham, NC

Has disclosed the following relevant financial relationships: Bayer, Janssen, Heartflow-Advisory Board, Consultant

#### ***Elissa Altin, MD***

Interventional Cardiologist, Yale-new Haven Hospital  
New Haven, CT

Has no relevant financial relationships to disclose.

#### ***Herbert Aronow, MD***

Director, Interventional Cardiology, Lifespan Cardiovascular Institute; Director, Cardiac Catheterization Labs, Rhode Island and the Miriam Hospitals  
Providence, RI

Has disclosed the following relevant financial relationships: Philips-Data Safety and Monitoring Board

### **Planner Disclosures**

No member of *CMEsolutions* or Cardiovascular Innovations Foundation has any relevant financial relationships to disclose.

### **Off-label Use**

This activity may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.

### **Commercial Support**

Commercial Support for this educational activity will be provided by the following:

- Boston Scientific
- Medtronic
- Philips

**Privacy Policy**

*CMEsolutions* Privacy and Confidentiality Policy: [www.online-med-edu.com/privacypolicy.pdf](http://www.online-med-edu.com/privacypolicy.pdf)

*CMEsolutions* can be contacted at [info@cmesolutions.org](mailto:info@cmesolutions.org).

**Software Requirements**

**PC**

Windows 2000 or higher

Internet Explorer 5.5 or Firefox

Adobe Acrobat Reader

**MAC**

Mac OS 10.2.8

Safari

Adobe Acrobat Reader